BidaskClub upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a buy rating to a strong-buy rating in a report issued on Wednesday.
ABUS has been the topic of several other reports. ValuEngine raised Arbutus Biopharma from a hold rating to a buy rating in a research note on Monday, April 2nd. Zacks Investment Research cut Arbutus Biopharma from a hold rating to a sell rating in a research note on Thursday, January 18th. Wedbush cut Arbutus Biopharma from an outperform rating to a neutral rating and reduced their price target for the stock from $9.00 to $6.00 in a research note on Monday, March 19th. Finally, Chardan Capital reaffirmed a buy rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $12.33.
Shares of ABUS stock opened at $6.10 on Wednesday. The firm has a market capitalization of $353.08 million, a P/E ratio of -3.41 and a beta of 1.05. Arbutus Biopharma has a twelve month low of $3.20 and a twelve month high of $8.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.86 and a current ratio of 16.86.
Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.03. The company had revenue of $1.40 million for the quarter. Arbutus Biopharma had a negative return on equity of 61.50% and a negative net margin of 705.09%. equities analysts anticipate that Arbutus Biopharma will post -1.56 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABUS. Foresite Capital Management IV LLC grew its stake in shares of Arbutus Biopharma by 886.3% in the first quarter. Foresite Capital Management IV LLC now owns 1,485,245 shares of the biopharmaceutical company’s stock worth $7,426,000 after acquiring an additional 1,334,653 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Arbutus Biopharma by 7,615.3% during the fourth quarter. BlackRock Inc. now owns 751,314 shares of the biopharmaceutical company’s stock valued at $3,794,000 after purchasing an additional 741,576 shares in the last quarter. Hudson Bay Capital Management LP lifted its holdings in shares of Arbutus Biopharma by 239.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock valued at $2,020,000 after purchasing an additional 282,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Arbutus Biopharma by 150.7% during the fourth quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock valued at $2,033,000 after purchasing an additional 241,963 shares in the last quarter. Finally, Eversept Partners LLC bought a new position in shares of Arbutus Biopharma during the fourth quarter valued at $543,000. 62.16% of the stock is currently owned by hedge funds and other institutional investors.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.